Indications for Intravenous Immunoglobulin (IVIG) Therapy
IVIG is primarily indicated for primary immunodeficiency diseases (PIDD) with significantly impaired antibody production, including X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID), severe combined immunodeficiency (SCID), and Wiskott-Aldrich syndrome 1, 2.
Primary (FDA-Approved) Indications
Immunodeficiency Disorders
- Primary immunodeficiency diseases with documented antibody deficiency are the cornerstone indication 1
- X-linked agammaglobulinemia
- Common variable immunodeficiency (CVID)
- Severe combined immunodeficiency
- Wiskott-Aldrich syndrome
- Combined immunodeficiencies with significantly impaired antibody production
Dosing for PIDD: 300-600 mg/kg every 3-4 weeks, with dose adjustments based on trough IgG levels and clinical response 2. Target maintaining adequate trough levels to prevent infections and organ damage (particularly bronchiectasis).
Other FDA-Approved Uses
Beyond primary immunodeficiency, FDA approval exists for 3:
- Immune thrombocytopenic purpura (ITP)
- Kawasaki disease
- Secondary immunodeficiency
- Pediatric HIV infection
- Prevention of graft-versus-host disease in bone marrow transplant
Secondary (Off-Label but Evidence-Based) Indications
Neurologic Disorders
Chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy represent the most common off-label uses, accounting for substantial IVIG consumption 4, 3. These conditions show strong evidence of benefit despite being off-label.
Additional neurologic indications with established efficacy 5:
- Guillain-Barré syndrome
- Myasthenia gravis
- Dermatomyositis
- Stiff person syndrome
Hematologic Disorders
Beyond ITP, IVIG is used for 4:
- Autoimmune hemolytic anemia
- Other immune-mediated cytopenias
Autoimmune/Inflammatory Conditions
Evidence supports use in 5:
- Autoimmune mucocutaneous blistering diseases
- Antineutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitides
- Graves' ophthalmopathy
- Selected forms of systemic lupus erythematosus
- Toxic epidermal necrolysis/Stevens-Johnson syndrome (dramatically reduces mortality)
Critical Clinical Considerations
When IVIG Is NOT Indicated
Do not use IVIG for 6:
- Asymptomatic hypogammaglobulinemia with normal antibody responses
- Selective IgA deficiency alone (without IgG deficiency)
- Transient hypogammaglobulinemia of infancy with normal antibody production
- IgG subclass deficiency without demonstrated functional antibody deficiency
Important Caveats
IgA deficiency is NOT a contraindication to IVIG therapy when IgG deficiency coexists 1. While anaphylaxis has been reported in rare IgA-deficient patients with high anti-IgA antibodies, this risk is extremely small. Consider subcutaneous immunoglobulin if prior anaphylaxis occurred with IVIG.
Avoid permanent central venous catheters solely for IVIG administration—subcutaneous immunoglobulin is a safer alternative for difficult venous access 1.
Monitoring Requirements
All patients on IVIG require regular monitoring 1:
- IgG trough levels every 6-12 months (more frequently in growing children)
- Complete blood counts
- Liver enzymes (hepatitis risk, though very low with modern preparations)
- Renal function (creatinine, BUN)—critical in high-risk patients
High-Risk Populations Requiring Caution
Administer at minimum dose and slowest infusion rate in patients with 2:
- Advanced age (>65 years)
- Pre-existing renal insufficiency
- Diabetes mellitus
- Hypercoagulable conditions or thrombosis history
- Cardiovascular risk factors
- Paraproteinemia
- Volume depletion
Thrombosis risk: Ensure adequate hydration before infusion and monitor blood viscosity in at-risk patients 2.
Current Usage Patterns
Real-world data shows immune-mediated conditions now represent 54% of IVIG use, with secondary immunodeficiency at 28% and primary immunodeficiency only 10% 4. Approximately 56% of IVIG infusions are for off-label FDA indications 4, though many have strong evidence support from professional guidelines.
The dramatic increase in IVIG consumption (417% over recent years) is primarily driven by autoimmune disease treatment 4, highlighting the expanding role beyond replacement therapy in immunodeficiency.